M
Michele Orditura
Researcher at Seconda Università degli Studi di Napoli
Publications - 208
Citations - 7454
Michele Orditura is an academic researcher from Seconda Università degli Studi di Napoli. The author has contributed to research in topics: Cancer & Cetuximab. The author has an hindex of 44, co-authored 191 publications receiving 6412 citations. Previous affiliations of Michele Orditura include Yahoo! & University of Padua.
Papers
More filters
Journal ArticleDOI
Treatment of gastric cancer.
Michele Orditura,Gennaro Galizia,Vincenzo Sforza,Valentina Gambardella,Alessio Fabozzi,Maria Maddalena Laterza,F Andreozzi,Jole Ventriglia,B. Savastano,Andrea Mabilia,Eva Lieto,Fortunato Ciardiello,Ferdinando De Vita +12 more
TL;DR: Recent evidence supports the use of second-line chemotherapy after progression in patients with good performance status, and perioperative and adjuvant chemotherapy, as well as chemoradiation, can improve outcome of resectable gastric cancer with extended lymph node dissection.
Journal ArticleDOI
Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy
TL;DR: Attention is focused on cetuximab and panitumumab, two mAb introduced recently into clinical practice for treatment of metastatic colorectal and head and neck cancer which target the external part of EGFR.
Journal ArticleDOI
Expression of Vascular Endothelial Growth Factor (VEGF) and Epidermal Growth Factor Receptor (EGFR) is an Independent Prognostic Indicator of Worse Outcome in Gastric Cancer Patients
Eva Lieto,Francesca Ferraraccio,Michele Orditura,Paolo Castellano,Anna La Mura,Margherita Pinto,Anna Zamboli,Ferdinando De Vita,Gennaro Galizia +8 more
TL;DR: Evidence is provided that contemporary evaluation of VEGF and EGFR expression may be crucial to select gastric cancer patients with poor prognosis who may benefit of tailored treatments.
Journal ArticleDOI
Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery.
Gennaro Galizia,Michele Orditura,Ciro Romano,Eva Lieto,Paolo Castellano,Pelosio L,Vincenzo Imperatore,Giuseppe Catalano,Carlo Pignatelli,Ferdinando De Vita +9 more
TL;DR: Preoperative serum levels ofIL-10 were shown to be useful markers for predicting both likelihood to perform curative surgery and, in combination with the 16th postoperative day IL-10 serum levels, tumor recurrence (predictive accuracy, 73.6 and 96%, respectively).
Journal ArticleDOI
A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients
F. De Vita,Michele Orditura,Elide Matano,Roberto Bianco,Chiara Carlomagno,S Infusino,Vincenzo Damiano,E Simeone,M. R. Diadema,Eva Lieto,Paolo Castellano,Stefano Pepe,S. De Placido,Gennaro Galizia,N. Di Martino,Fortunato Ciardiello,Giuseppe Catalano,Ar Bianco +17 more
TL;DR: Responsibility rate (RR), TTP and OS were comparable with those of other oxaliplatin-based regimens, suggesting a role for this combination in gastric cancer.